Table 3.

Incidence rate and hazard ratio for chronic kidney disease (CKD) in NAFLD compared to non-NAFLD patients in the sensitivity analyses.

	NAFLD Status	No of patients	Person years	No of events	Crude Incidence per 1000 person-years	Baseline covariates adjusted HR of CKD (95% CI)*
Patients with CKD diagnosis ≥ 6 months after baseline	NAFLD	261,158	707,016	4302	6.1	1.30 (1.25, 1.36)
	Non-NAFLD	765,552	1,567,022	6290	4.0	Reference
CKD diagnosis with 585.9 (unspecified CKD) ICD9 codes in addition to CKD stages 3–5	NAFLD	262,619	706,226	10615	15.0	1.28 (1.25, 1.32)
	Non-NAFLD	769,878	1,551,269	16364	10.5	Reference
A regression model controlling for HBV, HCV, and alcohol liver disease in addition to variables adjusted in primary analysis	NAFLD	262,619	707,310	5766	8.2	1.43 (1.38, 1.48)
	Non-NAFLD	769,878	1,572,889	8655	5.5	Reference

Abbreviations: NAFLD Non-alcoholic fatty liver disease, CKD chronic kidney disease, CI confidence interval, HR hazard ratio

^*Adjusted for age, gender, diabetes, hypertension, obesity, hyperlipidemia, coronary artery disease, peripheral vascular disease, cerebrovascular disease, heart failure, and chronic obstructive pulmonary disease , angiotensin-converting-enzyme inhibitors, and angiotensin II receptor blockers, mean number of outpatient visits, and mean number of inpatient visits, cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma.